Trial · NCT07893041
Exercise Rehabilitation to Improve Long-term Outcomes in Sarcoma Survivors.
NCT07893041, Not applicable, Completed, Curtin University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Exercise Rehabilitation to Improve Long-term Outcomes in Sarcoma Survivors. Trials, record NCT07893041. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07893041
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Exercise Rehabilitation to Improve Long-term Outcomes in Sarcoma Survivors.
- NCT number
- NCT07893041
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 25 participants, actual
- Lead sponsor
- Curtin University
- Conditions
- Sarcoma, Sarcoma of Bone and Connective Tissue, Sarcoma of Soft Tissue, Sarcoma of Bone
- Interventions
- Supervised Exercise Rehabilitation Program
- First posted
- 2026-10-23
- Last updated
- 2026-10-23
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | High-level Mobility Assessment Tool, HiMAT | Baseline (second of two assessments), 8 weeks, and 16 weeks | The HiMAT measures high-level walking-based mobility across 13 timed or scored items: walking forwards and backwards, walking on toes, stepping over an obstacle, running, skipping, hopping, bounding on each leg, and ascending and descending stairs. Scores sum to a total from 0 to 54. Higher scores indicate better mobility. The primary outcome is the change in total score from baseline to the end of the 8-week supervised exercise program, and the retention of that change at 16 weeks, after 8 weeks without supervised exercise. Baseline is the second of two baseline assessments, taken one week apart to confirm stability. A 4-point change is considered clinically meaningful. |
| Secondary | six-minute walk test distance | Baseline (second assessment), 8 weeks, 16 weeks | Participants walked back and forth between two points 50 m apart for 6 minutes. They covered as much distance as they could safely manage. The tester gave standardised phrases and no encouragement. Total distance in metres was recorded, along with pain in the affected limb and breathlessness at the end. Higher distance indicates better walking capacity. A change of 50 m is considered clinically meaningful. |
| Secondary | lower limb isokinetic strength (peak torque) | Baseline (second assessment), 8 weeks, 16 weeks | Knee extension and flexion peak torque measured bilaterally on an isokinetic dynamometer at 60 degrees per second, after warm-up repetitions. Values are normalised to body weight (Nm/kg). Hip abduction, adduction and flexion strength were also assessed by three-repetition maximum. Higher values indicate greater strength. |
| Secondary | lower limb joint range of motion | Baseline (second assessment), 8 weeks, 16 weeks | Active range of motion in degrees, measured with a goniometer or bubble inclinometer on both limbs. Joints: hip flexion and extension, knee flexion and extension, ankle dorsiflexion and plantar flexion. |
| Secondary | Toronto Extremity Salvage Score, lower limb | Baseline (second assessment), 8 weeks, 16 weeks | The 32-item lower limb version of the TESS, completed unassisted. Scores range from 0 to 100. Higher scores indicate better function |
| Secondary | SF-36 physical and mental component summary scores | Baseline (second assessment), 8 weeks, 16 weeks | The 36-item Short Form Health Survey, completed unassisted. Eight domains combine into a physical component summary (PCS) and a mental component summary (MCS). Higher scores indicate better perceived health. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07893041
GET https://conductscience.org/api/trials/v1/NCT07893041/registered